May Kin Ho

Dr. May Kin Ho is an Independent Director at Neumora Therapeutics, Inc., an Independent Director at BioMarin Pharmaceutical, Inc., an Independent Director at Agios Pharmaceuticals, Inc., a Managing Partner at Viridian Global Logistics, Inc. and a Venture Partner at Qiming Venture Partners Ltd. She is on the Board of Directors at Neumora Therapeutics, Inc., BioMarin Pharmaceutical, Inc., PAREXEL International Corp., Institute For Protein Innovation, Inc., Parexel International Corp.
Ltd., Agios Pharmaceuticals, Inc., The Aaron Diamond AIDS Research Center and Pelage Pharmaceuticals, Inc. Dr. Ho was previously employed as an Independent Director by GRAIL LLC, an Independent Director by Kyntra Bio, Inc., an Independent Director by PAREXEL International Corp., a Managing Director & Research Analyst by Goldman Sachs & Co. LLC, a Partner & Co-Head-Healthcare by The Goldman Sachs Group, Inc., a Director-Strategic Planning, Marketing & Research by Dupont De Nemours & Co., Inc., and a Director-Strategic Planning & Licensing by DuPont Merck Pharmaceutical Co. She received her undergraduate degree from State University of New York at Downstate Medical Center and a doctorate degree from State University of New York at Downstate Medical Center.